#China #Chengdu #Cancer Research #Kelun-Biotech #ASCO 2025

Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKEX: 6990) has announced its participation at the prestigious 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will showcase results from six critical clinical studies. Taking place in Chicago from May 30 to June 3, this annual event is a pivotal gathering for professionals engaged in oncology worldwide. The results presented will include innovative data on promising therapeutic advancements in oncology, highlighting the company's role in addressing significant medical needs in cancer treatment.

Key Studies to be Presented

The company will provide detailed insights into several cutting-edge therapies, including their novel TROP2 antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT), an anti-PD-L1 monoclonal antibody known as tagitanlimab, and the RET inhibitor KL590586 (A400/EP0031). The abstracts for these studies will be available on ASCO’s official website starting May 22, 2025, as anticipation builds around the findings. Here are some highlighted studies:

1. Sacituzumab tirumotecan (sac-TMT) in advanced EGFR-mutated non-small cell lung cancer (NSCLC) - This randomized OptiTROP-Lung03 study aims to investigate the efficacy of sac-TMT in patients who have not responded to previous treatments.
- Presentation Type: Oral
- Abstract Number: 8507
- Session Date: June 1, 2025, 8:00 AM-11:00 AM CDT

2. Tagitanlimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) - A randomized phase 3 study evaluating the combined approach against this aggressive form of cancer.
- Presentation Type: Oral
- Abstract Number: 6004
- Session Date: May 31, 2025, 1:15 PM-4:15 PM CDT

3. First-line treatment for unresectable locally advanced/metastatic Triple-Negative Breast Cancer (TNBC) - Early results from the Phase II OptiTROP-Breast05 trial will be unveiled.
- Presentation Type: Rapid oral
- Abstract Number: 1019
- Session Date: May 30, 2025, 2:45 PM-4:15 PM CDT

4. Combination therapy in advanced NSCLC - Examining the efficacy of sac-TMT in conjunction with tagitanlimab in a non-squamous cohort.
- Presentation Type: Poster
- Abstract Number: 8529
- Session Date: May 31, 2025, 1:30 PM-4:30 PM CDT

5. Preliminary results of sac-TMT in patients with uncommon EGFR mutations - Analyzing the impact of this ADC on patients with specific mutation patterns in NSCLC.
- Presentation Type: Poster
- Abstract Number: 8615
- Session Date: May 31, 2025, 1:30 PM-4:30 PM CDT

6. KL590586 in advanced RET-mutant medullary thyroid cancer - Updates on clinical trials emphasizing this promising next-generation selective RET inhibitor.
- Presentation Type: Poster
- Abstract Number: 6098
- Session Date: June 2, 2025, 9:00 AM-12:00 PM CDT

Innovations at Kelun-Biotech

Kelun's commitment to pioneering medical advancements is evident through sac-TMT, which targets advanced solid tumors, including lung and breast cancers. Its innovative approach employs a novel linker technology that enhances its efficacy and minimizes adverse effects. The company has garnered attention in the oncology field, having received approvals for its therapies in China and establishing partnerships for global commercialization.

In addition to sac-TMT, tagitanlimab stands out as the first PD-L1 monoclonal antibody approved for use in nasopharyngeal carcinoma, showcasing Kelun's forward-thinking approach in oncology.

Looking Ahead

With eight ongoing registrational clinical studies in China and numerous Phase 3 trials in collaboration with global partners like MSD, Kelun-Biotech is poised for significant impacts in the realm of cancer therapy. Their presentation at ASCO 2025 will not only highlight their ongoing research but also reinforce their mission to address the unmet medical needs in oncology for patients worldwide.

Stay tuned for more updates as Kelun-Biotech prepares to unveil these groundbreaking findings that may shape the future of cancer treatment. For additional information, visit Kelun-Biotech’s website.